Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Videos|December 24, 2021
The Psychedelic Drugs Currently Under Investigation for Potential FDA Approval
Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.
Advertisement
Pharmacy Times interviewed Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.
During the discussion, Ali addressed which psychedelic drugs are currently under investigation for potential FDA approval, whether cannabis is considered a psychedelic drug, and whether the FDA has approved and acknowledged the use of cannabis as a medical treatment.
Advertisement
Related to this article
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5